Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
doi:10.1016/j.otohns.2006.07.010
Precision signaling for next-level metabolic research
The analysis of 4887 participants treated with tirzepatide and 2,328 participants in the control groups identified 142 participants who developed at least one MACE-4p (inclusive of cardiovascular mortality, myocardial infarction, stroke, and hospitalization for unstable angina) and confirmed the cardiovascular safety with an hazard ratio (HR) of 0.80 (95% CI 0.571.11) for the comparison between tirzepatide and controls
LOX enzymatic activity was assessed in a fluorometric assay using supernatants from basal and doxycycline-incubated cells
US$ 20.99
US$ 29.96
US$ 22.56
US$ 21.27
US$ 28.07
US$ 27.67
